Reviva reports third quarter 2023 financial results and recent business highlights

- recover global phase 3 trial successfully met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains at week 4 with 50 mg of brilaroxazine vs. placebo in schizophrenia –
RVPH Ratings Summary
RVPH Quant Ranking